The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
The Chosun Ilbo on MSN
South Korea’s distinctive IV drip culture
I once turned back from visiting a nearby internal medicine clinic during lunchtime due to a cold. The waiting room was ...
FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many ...
For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common and associated with more severe symptoms, worse quality of life and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback